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Background: Approximately 80% of pancreatic ductal adenocarcinoma (PDAC) patients suffer from anorexia, weight loss,
and asthenia. Most PDAC patients receive chemotherapy, which often worsens their nutritional status owing to the adverse effects
of chemotherapy. Malnutrition of PDAC patients is known to be associated with poor prognosis; therefore, nutritional management
during chemotherapy is a key factor influencing the outcome of the treatment. Mobile apps have the potential to provide readily
accessible nutritional support for patients with PDAC.
Objective: We aimed to evaluate the efficacy of a mobile app–based program, Noom, in patients receiving chemotherapy for
PDAC.
Methods: We prospectively enrolled 40 patients who were newly diagnosed with unresectable PDAC from a single
university-affiliated hospital in South Korea, and randomly assigned them into a Noom user group (n=20) and a non-Noom user
group (n=20). The 12-week in-app interventions included meal and physical activity logging as well as nutritional education
feedback from dietitians. The non-Noom user group did not receive any nutrition intervention. The primary outcomes were the
changes in the nutritional status and quality of life (QoL) from the baseline to 12 weeks. The secondary outcomes included the
changes in the skeletal muscle index (SMI) from the baseline to 12 weeks. The European Organization for Research and Treatment
of Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) and the Patient-Generated Subjective Global Assessment
(PG-SGA) were used as paper questionnaires to assess the QoL and nutritional status of the patients. Intention-to-treat and
per-protocol analyses were conducted. Regarding the study data collection time points, we assessed the nutritional status and
QoL at the baseline (T0), and at 4 (T1), 8 (T2), and 12 (T3) weeks. Abdominal computed tomography (CT) imaging was conducted
at the baseline and after 8 weeks for tumor response and SMI evaluation. The skeletal muscle area (cm2) was calculated using
routine CT images. The cross-sectional areas (cm2) of the L3 skeletal muscles were analyzed.
Results: Between February 2017 and January 2018, 48 patients were assessed for eligibility. Totally 40 patients with pancreatic
cancer were included by random allocation. Only 17 participants in the Noom user group and 16 in the non-Noom user group
completed all follow-ups. All the study participants showed a significant improvement in the nutritional status according to the
PG-SGA score regardless of Noom app usage. Noom users showed statistically significant improvements on the global health
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status (GHS) and QoL scales compared to non-Noom users, based on the EORTC QLQ (P=.004). The SMI decreased in both
groups during chemotherapy (Noom users, 49.08±12.27 cm2/m2 to 46.08±10.55 cm2/m2; non-Noom users, 50.60±9.05 cm2/m2
to 42.97±8.12 cm2/m2). The decrement was higher in the non-Noom user group than in the Noom user group, but it was not
statistically significant (-13.96% vs. -3.27%; P=.11).
Conclusions: This pilot study demonstrates that a mobile app–based approach is beneficial for nutritional and psychological
support for PDAC patients receiving chemotherapy.
Trial Registration: ClinicalTrials.gov NCT04109495; https://clinicaltrials.gov/ct2/show/NCT04109495.
(JMIR Mhealth Uhealth 2021;9(8):e21088) doi: 10.2196/21088
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Introduction
Cancer cachexia is associated with poor therapeutic response,
treatment-related adverse events, and low quality of life (QoL)
in pancreatic ductal adenocarcinoma (PDAC) patients [1].
Approximately 80% of PDAC patients suffer from a wasting
syndrome known as “cancer anorexia-cachexia syndrome,”
which is characterized by anorexia, weight loss, asthenia, and
poor prognosis [2-7]. Patients with PDAC have high risk of
nutritional malabsorption and metabolic problems compared to
patients with other types of cancers, as the pancreas plays a
crucial role in exocrine and endocrine functions [8-11].
In addition, almost 80% of PDAC patients are not operable at
diagnosis and receive palliative chemotherapy [12].
Chemotherapy aggravates anorexia, nausea, vomiting, and
abdominal pain, which can also affect the patients’ QoL and
nutritional status. Unfortunately, studies on nutritional
evaluation and management of PDAC patients during
chemotherapy are insufficient. Malnutrition of PDAC patients
is associated with chemotherapy-induced toxicity, low adherence
to anticancer treatment, as well as poor QoL and
survival [2,4,6,13]. Therefore, research on the nutritional
management for PDAC patients during active treatment should
be considered.
Digital health care systems, especially mobile apps, have the
potential to provide readily accessible nutritional and
psychological support for cancer patients [14-23]. To date, there
has been no randomized controlled clinical trial to evaluate the
effectiveness of app-based programs targeting patients with
PDAC undergoing chemotherapy. The main purpose of this
pilot study was to evaluate the efficacy of mobile app–based
supportive care for PDAC patients in the aspects of nutritional
status, skeletal muscle index (SMI) change, and QoL.
Methods
Study Participants
In this randomized controlled trial (RCT) (Trial number NCT
04109495), the study participants were prospectively recruited
at a tertiary hospital in South Korea between February 2017
and January 2018. The inclusion criteria were as follows: (1)
males or females aged between 20 and 70 years; (2) patients
newly diagnosed with PDAC within the last 3 months and slated
to receive chemotherapy, (patients) able to access the Internet
through their mobile phones; and (4) patients able to read and
write Korean. The exclusion criteria were as follows: (1) history
of abdominal surgery within the past year and with plans to
undergo abdominal surgery; (2) acute illness or infection status
(pneumonia, sepsis, shock, etc.); (3) known chronic liver and
obstructive pulmonary diseases; (4) known absorption disorder
due to gastrointestinal (GI) mucosal disease (ulcerative colitis,
Crohn disease, acute and chronic diarrhea, etc.); (5) severe major
illness (heart failure, liver failure, kidney failure on
hemodialysis, etc.); (6) pregnancy or breastfeeding; (7) use of
steroids within the past month before recruitment; (8) being
diagnosed with or suspected of having peritoneal seeding or GI
obstruction; and (9) history of consuming nutritional
supplements.
Study Design
This study was a 12-week prospective, single-center,
nonblinded, RCT. The clinicians introduced this study to eligible
patients in the clinics, and the researchers met interested patients
and confirmed their eligibility. After obtaining written informed
consent, all patients were randomly assigned in a 1:1 ratio to
the Noom user group or non-Noom user group by the clinical
research coordinator (Figure 1). Treatment allocation was
performed by the randomized permuted block method using
random number tables. As this is a pilot study, we set a target
sample size of 40 patients considering the rules of thumb.
Browne cites a general flat rule to include at least 30 subjects
or more to estimate a parameter [24]. Owing to the nature of
the intervention, participant details could not be blinded. This
study was approved by the institutional review board of the
Severance Hospital (Approval number 1-2016-0061).
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Figure 1. Flow chart of the study recruitment process.
Interventions
Noom (Noom Inc.) is a mobile app for weight management that
is commercially available on Google Playstore and Apple
Appstore. Noom has a unique curriculum and human coaching
intervention, which is widely used in health and fitness
apps [25,26]. We adopted this program to the nutritional and
behavior intervention for PDAC patients undergoing
chemotherapy. The major goal of nutritional intervention was
to encourage caloric intake to maintain the nutritional status
and QoC of PDAC patients undergoing chemotherapy. Although
the commercialized version of the Noom app was designed for
weight loss and healthy dietary intake, we used functions such
as food logging, step count, weight logging, and messaging for
tracking balanced caloric intake and muscle gain. To achieve
this goal, the Noom app offered the following interventions:
(1) interactive interface with coach–participant messaging, (2)
daily articles for basic health knowledge, (3) food logging with
color coding, and (4) automated feedback-based food choices
(see Multimedia Appendix 1). The articles provided to patients
mainly included basic health knowledge, information on how
to organize a diet using calorie density, and exercise, and
lifestyle information. Patient-specific feedback was provided
by the coach. Participants were asked to log their weight by
self-report providing information on their meals and physical
activity in the app more than 4 days per week.
The coach, who is a clinical dietitian, provided nutritional
intervention based on the following goals: (1) Guide participants
to consume more calories than the recommended intake
calculated by the Harris–Benedict equation [27,28] with
additional disease-related energy requirements [29]. (2) Provide
more than four feedbacks per week on nutritional intake. (3)
Check the participants’ step counts and exercise logs once a
week to promote light physical activity. Noom aims to provide
nutritional support for PDAC patients through self-management
by monitoring their meals and in-app activities. The clinical
research coordinator helped the study participants download
the Noom app onto their mobile phones and register themselves
on the app. A unique username was generated with a personal
password. The study participants did not need to pay for
accessing Noom.
The participants in both the groups answered paper
questionnaires in the presence of the clinical research
coordinator and underwent blood tests at the baseline, and at 4,
8, and 12 weeks. The questionnaire items included the gender,
age, body weight, type of diagnosed digestive disease, treatment
method, status of oral nutritional supplements, and past medical
history of the patients. The European Organization for Research
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and Treatment of Cancer (EORTC) Quality of Life Core
Questionnaire (QLQ-C30, version 3.0) and the
Patient-Generated Subjective Global Assessment (PG-SGA)
were also used to assess the QoL and nutritional status of the
patients.
App activity was calculated as the summation of the recorded
events, including meals, exercise, weight input, number of
messages, and step counts. Participants with app activity for
more than 9 weeks were defined to be “above average users”
(10/40), and participants with app activity for less than 9 weeks
were defined to be “below average users” (7/40). A 9-week
period was determined based on the median value of the app
users’ activity.
Comparator
As opposed to the Noom user group, the non-Noom user group
did not have access to Noom. This group did not receive any
nutrition intervention and attended only study assessments.
They received the chemotherapeutic agent as usual. To reduce
the bias related to the usually prescribed appetite stimulant, the
subjects in both the groups who showed no statistical differences
received the same dosage of the appetite stimulant. In this study,
patients diagnosed with pancreatic cancer received
chemotherapy without regular nutritional intervention.
Variables
The primary objective was to investigate the changes in the
QoL or nutritional status, which were calculated from the
EORTC QLQ-C30 and the PG-SGA score, over time according
to Noom usage. The EORTC QLQ-C30 is a 30-item
cancer-specific questionnaire that incorporates 5 functional
scales (physical, role, cognitive, emotional, and social), 3
symptom scales (fatigue, pain, and nausea/vomiting), a global
health status (GHS) and QoL scale, several single items
assessing additional symptoms commonly reported by cancer
patients (dyspnea, loss of appetite, insomnia, constipation, and
diarrhea), and the financial impact of the disease [30]. A higher
score on the GHS and QoL scales indicates a good QoL, but a
higher score on the symptom scales indicates poor QoL.
The PG-SGA is a scoring method for nutritional measurement
integrating body weight, food intake, nutritional difficulties and
activities, and therapeutic information provided by physicians. A
score ≥9 indicates a critical need for nutritional intervention [31].
Several studies have verified that the PG-SGA is a reliable and
valid assessment of the nutritional status of cancer patients;
therefore, we used the PG-SGA scale as a nutritional status
assessment tool [14,32-34]. A trained nurse assessed all the
PG-SGA scores to maintain consistency in the test results.
The secondary objective was to observe changes in the SMI
according to Noom usage. We evaluated whether the SMI was
associated with Noom usage at the baseline and during the
follow-up period. The skeletal muscle area (cm2) was calculated
using routine computed tomography (CT) images through the
picture archiving and communication system (PACS), an image
system using Image J software (US National Institutes of
Health) [35,36]. Cross-sectional areas (cm2) of the L3 skeletal
muscles were analyzed using Image J. At the L3 level, the field
of view included the psoas, paraspinal muscles, and abdominal
wall muscles. Currently, the most frequently used landmark in
the body composition imaging studies for sarcopenia is the L3
level [37]. We segmented the tissues based on the Hounsfield
unit of CT scanning using Image J with assistance from a
well-trained and an experienced medical doctor. We had
previously published several studies using this method [38,39].
The skeletal muscle area was normalized for height (m2) and
calculated as the SMI (cm2/m2) [40].
Age, sex, BMI, Eastern Cooperative Oncology Group
performance status (ECOG PS), smoking history, tumor extent,
tumor size, chemotherapy regimen, and laboratory
characteristics (leukocyte, hemoglobin, platelet, albumin,
creatinine, and carbohydrate antigen [CA] 19-9) were also
examined.
In this study, we attempted to remove the confounding factors
such as steroid ingestion, including appetite stimulants,
megestrol, and herbs. Clinicians used to prescribe megestrol to
stimulate the appetite of cancer patients. To reduce the
confounding factors with respect to appetite stimulants, we
prescribed the same dose of megestrol (160 mg/day) for all the
enrolled patients, except for those who showed good appetite
without stimulants. The prescription was confirmed by the
clinical judgment of the attending physician.
Statistical Analysis
Data are expressed as the median, n (%), or n, as appropriate.
Variables were compared using Chi-square tests or Fisher exact
tests for categorical data and Student t tests for continuous
variables to evaluate the statistical significance of the differences
in the baseline characteristics between Noom and non-Noom
users. Variables related to the in-app actions of the above
average and below average user groups were compared using
the Mann-Whitney test. The primary outcomes of the nutritional
status and QoL, as measured by the PG-SGA and EORTC QLQ,
were analyzed using intention-to-treat analysis and linear mixed
models. Intention-to-treat analysis with the last observation
carried forward was applied to account for missing data. The
secondary outcome of SMI was assessed in a per-protocol
analysis, using the Mann-Whitney test. P<.05 was considered
to indicate statistical significance. Statistical analyses were
performed using the SPSS (version 23.0, IBM Corp.).
Results
Patient Characteristics
Between February 2017 and January 2018, 48 patients were
assessed for eligibility. A total of 40 patients were enrolled and
randomized into 2 groups (Noom users, n=20; non-Noom users,
n=20) (Figure 1). After 7 patients dropped out, 17 Noom users
and 16 non-Noom users completed all the follow-ups. Attrition
was 18% (7/40 participants), including 2 patients (one in the
Noom user group and another in the non-Noom user group)
who could not continue chemotherapy owing to severe sepsis
or progression of disease, and 5 patients (2 in the Noom user
group and 3 in the non-Noom user group) who withdrew their
informed consent. The baseline variables in Table 1 did not
show a significant difference between participants who were
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included in the intention-to-treat population (n=40) and
per-protocol population (n=33).
The median age was 61.5 years (range 34-78 years), and 25 of
the 40 patients (63%) were male. All the recruited patients had
unresectable PDAC at the time of diagnosis. The baseline
characteristics did not show statistically significant differences
between the 2 groups, except for the baseline BMI and
hemoglobin. Most of the patients received palliative folinic
acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX)
as a first-line chemotherapy (17/20 [85%] of Noom users and
18/20 [90%] of non-Noom users).
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Table 1. Baseline characteristics of the study population.

















Age, median, years (range)
.8310 (62.5)10 (58.8).9912 (60)13 (65)Sex, male, n (%)
.951.63 ± 0.081.63 ± 0.09.71.63±0.091.63±0.09Height (m)
.2262.8 ± 10.958.2 ± 8.4.1863.5 ± 11.358.4±7.9Weight (kg)
.0423.46 ± 2.5721.83 ± 1.69.0323.5 ± 2.7221.91 ± 1.57BMI (kg/m2)










2 (12.5)3 (17.6)2 (10)3 (15)2-3
Smoking history
.7114 (87.5)14 (82.4).4714 (70)16 (80)Never
2 (12.5)3 (17.6)6 (30)4 (20)Former or current
.995 (31.3)5 (29.4).726 (30)5 (25)DM,d n (%)








































Initial CAg 19-9, U/mL
.1812 (75)16 (94.1).3416 (80)19 (95)Elevated initial CA 19-9, U/mL
Clinical stage, n (%)
.614 (25)4 (23.5).936 (30)6 (30)Borderline resectable
6 (37.5)4 (23.5)6 (30)5 (25)Locally advanced
6 (37.5)9 (52.9)8 (40)9 (45)Metastatic
.654.5±2.24.2±1.3.84.2±2.14.2±1.3Tumor size, cm
Chemotherapy regimen, n (%)
.9914 (87.5)14 (82.4).9918 (90)17 (85)FOLFIRINOXh
2 (12.5)3 (17.6)2 (10)3 (15)Gem/Nab-paclitaxeli
aData are presented as n (%) for categorical variables and as median (interquartile range) or mean±SD for continuous variables.
bP values were calculated by Student t tests for continuous data and Chi-square or Fisher exact tests for categorical data.
cECOG PS: Eastern Cooperative Oncology Group performance status.
dDM: diabetes mellitus.
eThe skeletal muscle index was calculated from the muscle cross-sectional area (cm2)/height (m)2 of the lumbar muscle.
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fWBC: white blood cells.
gCA: carbohydrate antigen.
hFOLFIRINOX: folinic acid, fluorouracil, irinotecan, and oxaliplatin.
iGem/Nab-paclitaxel: gemcitabine/nanoparticle albumin–bound paclitaxel.
The baseline characteristics of the Noom participants, above
average and below average users, are shown in Table 2. The
values in Table 2 were calculated by per-protocol analysis, as
patients who dropped out (n=7) did not complete the entire
9-week period, which is the median value of the app users’
activity. The 17 Noom users were divided as follows: 10 above
average users and 7 below average users. There were no baseline
differences in the sex, age, and baseline BMI between the 2
Noom user groups (Table 2, sex, 59% vs. 60%; age, 62 vs. 62.5
years; baseline BMI, 21.8 vs. 21.5).
Table 2. Baseline characteristics of Noom users.
Below average users (n=7)Above average users (n=10)Noom users (N=17)Variablesa
Baseline
4 (57.1)6 (60)10 (58.8)Sex, male, n (%)
62 (58-65)62.5 (45-70)62 (45-70)Age, median, years (range)
1.61 ± 0.081.64±0.11.63±0.09Height (m)
58.04±8.7558.32±8.6158.2±8.4Weight (kg)
22.24±2.0221.54±1.4621.83±1.69BMI (kg/m2)
aP values were calculated by the Mann-Whitney test between the two user groups.
In the intention-to-treat population, 15 of the 20 Noom users
(75%) and 14 of 20 non-Noom users (70%) received megestrol,
but there was no significant difference in the number of
prescribed patients (P=.72) and the total dose of the drug (9,440
mg vs. 12,240 mg, P=.06). In the per-protocol population, 12
of the 17 Noom users (71%) and 13 of the 16 non-Noom users
(81%) received metestrol, but there was no significant difference
in the number of prescribed patients (P=.69) and the total dose
of the drug (11,120 mg vs. 12,320 mg, P=.09).
Improvement of Nutritional Status Through Mobile
App Usage
In the intention-to-treat analysis, all the study participants
showed a significant improvement in the nutritional status
according to the PG-SGA score regardless of Noom app usage
(Figure 2A, P=.001). In the per-protocol analysis, the above
average users showed a significant improvement in the PG-SGA
score (Figure 2B, P=.03).
Figure 2. Change in PG-SGA score according to Noom usage over time. (A) All study participants show an improvement in nutritional status according
to the PG-SGA score (P=.001). (B) All Noom users show improvement in their nutritional status according to the PG-SGA score regardless of their
app activity differences. Above average users showed significant improvement in PG-SGA score (P=.03). PG-SGA: Patient-Generated Subjective
Global Assessment.
There were significant differences in the total protein and energy
intakes between the above average and below average users
(Table 3, 1.3 vs. 1g/kg/day, P=.02; 25.2 vs. 17.7 kcal/kg/day,
P=.04). In the per-protocol analysis, 7 of the 10 above average
users (70%) met the individual minimum protein intake
requirement, and 6 of the 10 above average users (60%) met
the individual minimum energy intake requirement. However,
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none of the below average users met the minimum recommended
daily intake of protein and calories.
The above average users documented meal data more frequently
in the Noom app (15.4 meals per week vs. 5.06 meals per week)
and showed an increase in their body weight and BMI compared
to the below average users (Table 3, body weight, +1.16% vs.
-4.43%; BMI, +0.21 vs. -0.81).
Table 3. Effects of Noom app intervention on dietary intake, weight, BMI, and engagement characteristics.
Below average users (n=7)Above average users (n=10)Noom users (N=17)Variables
12 weeks
1 (0.5-1)1.3 (0.9-1.6)a1 (0.6-1.4)Total protein intake(g/kg/day)





5.06±3.9515.41±6.76f11.15±7.69Meal input frequency (meals per week)
0.14±0.385.6±10.28g3.35±8.19Total exercise input frequency (every 12 weeks)
0.27±0.331.47±2.30.98±1.84Articles read (articles/week)
0.27±0.650.83±0.70.6±0.72Number of weight inputs (times/week)
3.63±7.036.19±4.355.14±5.56Messages to coach (messages/week)
7,409.17±6,951.7923,999.58±24,595.55h17,168.23±20,718.02Steps recorded (steps/week)
aThere was a significant difference in the total protein intake during the 12 weeks between above average and below average users; P=.02. The P value
was calculated by Mann-Whitney tests.
bThere was a significant difference in the total energy intake during the 12 weeks between above average and below average users; P=.04.
cThere was no significant difference in the changes at 12 weeks between the above average and below average users; P=.10.
dThere was no significant difference in the changes at 12 weeks between the above average and below average users; P=.09.
eP values were calculated by Mann-Whitney tests between the 2 user groups.
fAll the changes from the baseline to 12 weeks were significant in the above average and below average users; P=.007.
gAll the changes from the baseline to 12 weeks were significant in the above average and below average users; P=.01.
hAll the changes from the baseline to 12 weeks were significant in the above average and below average users; P=.02.
Improvement in QoL Through Mobile App Usage
There was no statistically significant difference in the EORTC
QLQ score between the Noom users and non-Noom users
(Figure 3A). However, on the GHS and QoL scale, there was
a statistically significant improvement in the Noom user group
compared to the non-Noom user group during the study period
(Figure 3B, P=.004).
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Figure 3. Change in EORTC QLQ-C30 scores according to Noom usage over time. (A) There was no statistically significant difference in EORTC
QLQ score between the Noom users and non-Noom users. (B) Noom users showed more statistically significantly improvement on the GHS and QoL
scale compared to the non-Noom users over time (P=.004). *P values were calculated by the linear mixed model. EORTC QLQ-C30: European
Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; GHS: global health status; QoL: quality of life.
Skeletal Muscle Change After Mobile App Usage
When receiving chemotherapy, the SMI decreased in both
groups (Noom users, 49.08±12.27 cm2/m2 to 46.08±10.55
cm2/m2; non-Noom users, 50.60±9.05 cm2/m2 to 42.97±8.12
cm2/m2). The decrement was higher in non-Noom user group
than in the Noom user group, but it was not statistically
significant (-13.96% vs. -3.27%; P=.11). In the per-protocol
analysis, there was a statistically significant increment in the
SMI of the above average user group compared to the non-Noom
user group (Figure 4, +5.58% vs. -13.96%; P=.04).
Figure 4. Change in SMI from baseline at 8 weeks. Above average users showed a statistically significant increase in muscle mass after 2 months of
Noom usage compared to non-users (P=.04). *P values were calculated by Mann-Whitney tests between the 2 groups. SMI: skeletal muscle index.
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Chemotherapy Response According to Mobile App
Usage
Furthermore, the overall best response to chemotherapy
according to Noom usage was also analyzed in the per-protocol
analysis. The overall best response was defined as the best
response recorded from the start of chemotherapy until disease
progression, recurrence, or the start of new chemotherapy
sessions. A decrease in the tumor size was more prominent in
the above average users than in the non-Noom users, although
this was not statistically significant, possibly owing to the small
study population (-15.6% vs. -6.3%; P=.17).
There were no differences in terms of the progression-free
survival, overall survival, and duration of chemotherapy between
the Noom users and non-Noom users.
Discussion
Principal Findings
Mobile apps have been used in the management of chronic
diseases such as obesity and hypertension, as well as exercise
measurement; they were rarely used directly in hospital care
settings. To the best of our knowledge, this is the first study
that evaluates the short-term effects of mobile app–based
coaching on the change in the nutritional status, SMI, and QoL
during PDAC management. The above average Noom users in
this pilot study showed statistically significant improvements
in their nutritional status. The SMI significantly increased in
the above average users compared to the non-Noom users.
Moreover, the Noom users showed statistically significant
improvements in QoL compared to the non-Noom users based
on the GHS and QoL scales of the EORTC QLQ. These findings
showed that PDAC patients who receive chemotherapy could
be supported by mobile app–based coaching for improving their
nutritional and health conditions.
Previous studies have highlighted the importance of supportive
care for patients with advanced cancer, including PDAC. Early
palliative supportive care led to significant improvements in
nutritional statuses, QoL, depression levels, and symptom
burden [41-44]. In particular, malnutrition during chemotherapy
can induce various adverse effects in humans owing to
dysfunction of the intestinal mucosa, decreased immune
function, decreased functioning of major organs such as the
liver, kidney, and heart, and changes in drug
dynamics [10,45-48]. We hypothesized that early nutritional
supervision as a supportive treatment could improve the
nutritional and psychological conditions of patients with PDAC.
In particular, we used a mobile app with human coaching as a
nutritional support tool. Even though both groups showed
improvements in the PG-SGA score regardless of the frequency
of Noom app usage, the above average users showed significant
improvements in the PG-SGA scores after using the app. Britton
et al reported that the minimum significant difference for the
PG-SGA score was 2 points [49]. In this study, the PG-SGA
score improved by more than 2 points at 12 weeks in all groups,
indicating clinical significance. Therefore, PDAC patients
receiving chemotherapy could benefit from using the Noom
app, in addition to the usual palliative care.
There have been some attempts at evaluating the efficacy of
mobile apps for assisting cancer patients. One randomized study
on 114 women with breast cancer who were starting
chemotherapy found that e-support program users had better
outcomes at 12 weeks for self-efficacy, symptom interference,
and QoL compared to users in the control group [15]. Our study
also confirmed that QoL improved after using the mobile app.
However, the app content used in the two studies differed. Apps
used in the Chinese study focused on self-efficacy, social
support, and symptom management for patients, whereas the
app used in our study focused on nutritional management.
Another systematic review also revealed the benefits of
app-based programs on the physical activity level, dietary
behavior, and health-related QoL in populations diagnosed with
solid tumors [50]. Similarly, in our study, the above average
users showed better dietary behavior such as inputting their
meal data more frequently, with more of them meeting the
individual minimum protein and energy intake requirements
compared to the below average users. Furthermore, the above
average users showed significant improvement in their
nutritional status at 12 weeks based on the PG-SGA score. In
the present study, the patients had an average PG-SGA score
≥9 points at the baseline, which indicates that almost all
participants needed nutritional intervention [2,6,51].
According to previous studies, malnutrition, weight loss, and
sarcopenia are risk factors strongly associated with limited
tolerance for chemotherapy, short survival times, and poor QoL
in PDAC patients. We calculated the SMI using the sarcopenia
measurement method. Sarcopenia was measured by CT-based
skeletal muscle area assessment, as in many previous
studies [52,53]. Loss of skeletal muscle mass is known to be
associated with cancer cachexia [54,55]. In the present study,
when undergoing chemotherapy, the above average Noom users
showed an increment in the SMI, and there was a significant
difference between them and the non-Noom users. We assumed
that Noom users would be more motivated to improve nutritional
intake while monitoring their food intake through the app, and
human coaches who are professional nutritionists may have
helped Noom users obtain proper nutrition.
A previous retrospective study suggested that early nutritional
intervention may affect the overall survival of PDAC patients
undergoing chemotherapy [8]. In this study, nutritional
intervention included face-to-face dietary consultation with a
dietitian. Several studies reported that malnutrition and
sarcopenia are factors that are strongly associated with limited
tolerance for chemotherapy [3,11]. Despite the increasing
evidence demonstrating an association between the nutritional
status and clinical outcomes, there is no standard nutritional
management tool for PDAC patients undergoing chemotherapy.
Although the overall best response to chemotherapy according
to Noom usage was not statistically significant, further
confirmatory research is needed to achieve better results.
We did not analyze the factors associated with high usage of
the app. Although we did not perform statistical analysis, clinical
dieticians who coached the patients considered sex as a relevant
factor. Female patients or caregivers were considered to use the
Noom app more frequently. Further, male patients under 60
years of age were considered to use the Noom app more often.
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We believe that further studies on mobile app usage according
to the age, sex, and education level of patients and their
caregivers, as well as the performance status of the patients will
benefit future research on nutritional interventions for cancer
patients.
Comparison With Prior Work
Most of the nutritional studies on pancreatic cancer patients
undergoing chemotherapy have been performed with
face-to-face interventions [56]. Expert dieticians provided
essential dietary suggestions and prescribed oral nutritional
supplements. These studies have shown positive outcomes, such
as improved weight and QoL [8,57,58]. Bauer et al [57] found
that cancer patients who received weekly counseling by a
dietitian and were advised to consume protein- and energy-dense
oral nutritional supplements showed clinically significant
improvements in their nutritional status and QoL. Our findings
showed a higher improvement in QoL (median change 33.3 vs.
16.7) but lower improvement in nutritional status based on the
PG-SGA score (median change 4.5 vs. 9) than those observed
in the study by Bauer et al [57], although a direct comparison
between the studies was difficult. However, face-to-face studies
have limitations in terms of time and space. Mobile health
technology is an innovative way to overcome this limitation.
Face-to-face interventions can give feedback only on the day
of intervention, but with mobile apps, coaches can provide
immediate feedback daily based on the patients’ meal records.
In addition, face-to-face nutritional education is unlikely to be
implemented universally owing to time and space constraints.
On the other hand, it has the advantage of providing personalized
education for patients through their meal records using mobile
apps.
Limitations
Our study had several limitations. First, this study could not
evaluate the long-term effect of the Noom app, as we conducted
this pilot study over a period of only 12 weeks. Further research
on the long-term effect of mobile apps on PDAC patients is
needed. Second, the study participants were recruited from a
single center, and the sample size was small. Furthermore, the
requirement of access to the mobile app may have resulted in
the participation of a more educated population, potentially
limiting the generalization of this study. However, as the number
of people familiar with using mobile apps increases over time,
it is expected that supportive care using mobile apps could
become a promising intervention method. Therefore, additional
multicenter-mediated validation is needed to confirm the results
of this study. However, one of the strengths of this study was
it is the first such study to investigate the use of a mobile app
in providing supportive care to PDAC patients. Third, the
baseline BMI differed between the Noom users and non-Noom
users. The Noom users had a lower BMI at the time of diagnosis
compared to that of the non-Noom users. However, the BMI
changes in the between the 2 groups did not differ significantly
at 12 weeks (P=.99). Therefore, the baseline BMI differences
between the 2 groups did not affect the results. Furthermore,
SMI reduction was more prominent in the non-Noom users than
in the Noom users, despite the higher baseline SMI in the
non-Noom users. Fourth, we could not measure the nutritional
intake of the non-Noom users owing to the study design;
therefore, it was not possible to analyze whether the Noom users
consumed more calories and specific nutrients compared to the
non-Noom users.
Conclusions
This pilot study demonstrated that a mobile app–based approach
for providing nutritional and psychological support could be
beneficial for patients with PDAC undergoing chemotherapy.
Mobile apps could be useful tools for providing prompt and
appropriate nutritional support and monitoring of PDAC
patients.
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ECOG PS: Eastern Cooperative Oncology Group performance status
EORTC: European Organization for Research and Treatment of Cancer
FOLFIRINOX: folinic acid, fluorouracil, irinotecan, and oxaliplatin
GHS: global health status
GI: gastrointestinal
PACS: picture archiving and communication system
PDAC: pancreatic ductal adenocarcinoma
PG-SGA: Patient-Generated Subjective Global Assessment
QLQ-C30: Quality of Life Core Questionnaire
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